Compare Stocks

Date Range: 

 Arbutus BiopharmaCymaBay TherapeuticsOncternal TherapeuticsCorMedixProQR Therapeutics
SymbolNASDAQ:ABUSNASDAQ:CBAYNASDAQ:ONCTNYSEAMERICAN:CRMDNASDAQ:PRQR
Price Information
Current Price$2.78$3.98$5.35$7.92$5.83
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.61.71.21.4
Analysis Score3.43.54.53.53.5
Community Score2.83.03.32.52.5
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.00.8
Earnings & Valuation Score0.60.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$6.50$11.77$15.20$19.30$30.86
% Upside from Price Target133.81% upside195.71% upside184.11% upside143.69% upside429.28% upside
Trade Information
Market Cap$285.16 million$290.96 million$295.69 million$318.64 million$310.77 million
Beta3.151.451.662.710.73
Average Volume2,271,8151,066,2961,623,0371,063,9082,862,839
Sales & Book Value
Annual Revenue$6.01 millionN/A$2.42 million$280,000.00N/A
Price / Sales44.56N/A109.131,075.54N/A
CashflowN/AN/AN/A$0.21 per shareN/A
Price / CashN/AN/AN/A37.85N/A
Book Value($1.00) per share$2.71 per share$0.93 per share$0.92 per share$2.11 per share
Price / Book-2.78N/A5.758.61N/A
Profitability
Net Income$-153,720,000.00$-102,810,000.00$-34,190,000.00$-16,430,000.00$-63,560,000.00
EPS($1.62)($1.46)($1.56)($0.89)($1.55)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-1,163.48%N/A-746.10%-10,214.42%N/A
Return on Equity (ROE)N/A-34.86%-150.58%-86.52%-62.92%
Return on Assets (ROA)-59.66%-32.23%-91.87%-70.16%-47.69%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.24%
Current Ratio15.94%15.88%3.01%8.45%8.52%
Quick Ratio15.94%15.88%3.01%8.40%8.52%
Ownership Information
Institutional Ownership Percentage28.44%84.28%10.79%25.91%55.87%
Insider Ownership Percentage6.70%4.00%10.90%5.00%N/A
Miscellaneous
Employees76411230154
Shares Outstanding96.34 million68.95 million49.36 million38.02 million50.21 million
Next Earnings Date8/6/2021 (Estimated)5/10/2021 (Estimated)5/6/2021 (Confirmed)5/10/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
ProQR: Q1 Earnings SnapshotProQR: Q1 Earnings Snapshot
sfgate.com - May 6 at 8:30 AM
ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development PactProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact
finance.yahoo.com - May 4 at 1:33 PM
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed TargetProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
finance.yahoo.com - May 4 at 8:33 AM
ProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR) Short Interest Update
americanbankingnews.com - May 3 at 4:42 PM
ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Stifel NicolausProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Stifel Nicolaus
americanbankingnews.com - May 3 at 8:40 AM
ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Up 48.1% YTD, Predicting What To Expect AheadProQR Therapeutics N.V. (NASDAQ:PRQR) Are Up 48.1% YTD, Predicting What To Expect Ahead
marketingsentinel.com - May 1 at 9:16 AM
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
finance.yahoo.com - April 23 at 8:25 AM
For Risk-Tolerant Investors, ProQR Therapeutics N.V. (NASDAQ:PRQR) Is Worth A ShotFor Risk-Tolerant Investors, ProQR Therapeutics N.V. (NASDAQ:PRQR) Is Worth A Shot
marketingsentinel.com - April 22 at 1:03 PM
ProQR Announces Participation in Upcoming Kempen Life Sciences ConferenceProQR Announces Participation in Upcoming Kempen Life Sciences Conference
finance.yahoo.com - April 22 at 8:03 AM
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by BrokeragesProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - April 19 at 10:50 AM
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
finance.yahoo.com - April 13 at 8:28 PM
Why should you add ProQR Therapeutics N.V. (PRQR) to your portfolio?Why should you add ProQR Therapeutics N.V. (PRQR) to your portfolio?
marketingsentinel.com - April 12 at 1:03 PM
Shark Bites: Taking Advantage of Weak Biotechnology ActionShark Bites: Taking Advantage of Weak Biotechnology Action
realmoney.thestreet.com - April 8 at 1:46 PM
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional SharesProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - April 5 at 6:50 PM
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and ...ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and ...
apnews.com - April 2 at 6:44 PM
ProQR Prices $90 Million Underwritten Public Offering of Ordinary SharesProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - March 30 at 11:13 PM
ProQR Announces Proposed Underwritten Public Offering of Ordinary SharesProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - March 30 at 6:13 PM
Analyst Lights Up Over ProQR Blindness Trial ResultsAnalyst Lights Up Over ProQR Blindness Trial Results
finance.yahoo.com - March 26 at 5:32 PM
ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome TrialProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial
streetwisereports.com - March 25 at 8:57 PM
Why ProQR Therapeuticss Stock is Up During Todays SessionWhy ProQR Therapeutics's Stock is Up During Today's Session
benzinga.com - March 25 at 3:57 PM
PRQR Stock: 7 Things to Know About High-Flying ProQR TherapeuticsPRQR Stock: 7 Things to Know About High-Flying ProQR Therapeutics
feedproxy.google.com - March 25 at 2:52 PM
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to ...ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to ...
apnews.com - March 25 at 10:53 AM
Market Analysts see ProQR Therapeutics N.V. [PRQR] gaining to $22. Time to buy?Market Analysts see ProQR Therapeutics N.V. [PRQR] gaining to $22. Time to buy?
dbtnews.com - March 25 at 10:53 AM
ProQR’s RNA therapy on track to pivotal tests in rare, inherited form of vision lossProQR’s RNA therapy on track to pivotal tests in rare, inherited form of vision loss
medcitynews.com - March 24 at 7:53 PM
Why ProQR Therapeutics Stock Is Popping TodayWhy ProQR Therapeutics Stock Is Popping Today
fool.com - March 24 at 1:46 PM
DateCompanyBrokerageAction
3/10/2021Arbutus BiopharmaB. RileyLower Price Target
3/10/2021Arbutus BiopharmaHC WainwrightReiterated Rating
2/25/2021Arbutus BiopharmaJefferies Financial GroupInitiated Coverage
11/16/2020Arbutus BiopharmaChardan CapitalReiterated Rating
7/27/2020Arbutus BiopharmaJMP SecuritiesInitiated Coverage
7/24/2020Arbutus BiopharmaRobert W. BairdDowngrade
5/19/2020Arbutus BiopharmaWedbushUpgrade
10/4/2019Arbutus BiopharmaEchelon Wealth PartnersDowngrade
3/31/2021CymaBay TherapeuticsCantor FitzgeraldLower Price Target
3/9/2021CymaBay TherapeuticsPiper SandlerReiterated Rating
11/30/2020CymaBay TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
11/30/2020CymaBay TherapeuticsSmith Barney CitigroupBoost Price Target
11/6/2020CymaBay TherapeuticsRaymond JamesBoost Price Target
11/6/2020CymaBay TherapeuticsSVB LeerinkBoost Price Target
9/29/2020CymaBay TherapeuticsLifesci CapitalReiterated Rating
9/10/2020CymaBay TherapeuticsOppenheimerReiterated Rating
8/3/2020CymaBay TherapeuticsStifel NicolausBoost Price Target
3/30/2021Oncternal TherapeuticsBrookline Capital ManagementReiterated Rating
3/30/2021Oncternal TherapeuticsBrookline Capital AcquisitionInitiated Coverage
2/23/2021Oncternal TherapeuticsNorthland SecuritiesInitiated Coverage
2/17/2021CorMedixNeedham & Company LLCInitiated Coverage
9/21/2020CorMedixTruistInitiated Coverage
12/6/2018CorMedixRoth CapitalReiterated Rating
8/11/2019ProQR TherapeuticsRoyal Bank of CanadaReiterated Rating
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.